Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "RMAT"

1996 News Found

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
Clinical Trials | March 14, 2026

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days


GelMEDIX partners with Catalent to advance vision-restoring cell therapies
News | March 14, 2026

GelMEDIX partners with Catalent to advance vision-restoring cell therapies

The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing


Single-use gloves misused across India, raising health risks
Healthcare | March 14, 2026

Single-use gloves misused across India, raising health risks

One task, one interaction, one pair, experts advocate


Citius Oncology reports promising early trial results for therapy for gynecologic cancers
Clinical Trials | March 14, 2026

Citius Oncology reports promising early trial results for therapy for gynecologic cancers

The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR


FDA nod to first treatment for rare genetic brain disorder
Drug Approval | March 12, 2026

FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature


Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
Biopharma | March 10, 2026

Lifecore Biomedical teams up with Indomo to advance at-home acne therapy

Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation


Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
Medical Device | March 10, 2026

Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation

Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings